INTERNAL MEDICINE

The MOMENTUM study reveals that more than one-quarter of patients with resistant hypertension have underlying endogenous hypercortisolism. Often lacking classic phenotypic signs, this “lurking” endocrine driver highlights the critical need for routine biochemical screening and endocrinology referral in this high-risk population.

Baxdrostat lowers BP in resistant hypertension, offering a new treatment option.

Metabolic syndrome raises Parkinson’s risk by 39%, especially with genetic predisposition.